LAG3 and cancer: In this study, we constructed a bivalent bispecific aptamer (HLB-apt) targeting LAG3 and HER2 simultaneously, which recruits T cells to HER2-expressing cancer cells, thereby enhancing the anti-cancer immune response in vitro and in vivo (Figure 1).